The Proposed Rule (cont.)
62FR 43900, August 15, 1997
to ensure that new drugs and biological products that are likely to be commonly used in children or that represent a meaningful therapeutic benefit over existing treatments for children contain adequate pediatric labeling for the approved indications at the time of, or soon after, approval.